Evidence map›Paper›PMID 26423946›Full record

ArticleJournal of virology2015

Flavivirus Infection Impairs Peroxisome Biogenesis and Early Antiviral Signaling.

Jaehwan You, Shangmei Hou, Natasha Malik-Soni, Zaikun Xu, Anil Kumar, Richard A Rachubinski, Lori Frappier, Tom C Hobman

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed
6.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 96 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Evolutionary remodeling of a remnant GET pathway factor into PEX38, an essential peroxin.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. The peroxisome: an update on mysteries 3.0.Histochemistry and cell biology · 2024
    Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Jaehwan YouDepartment of Cell Biology, University of Alberta, Edmonton, Canada.
Shangmei HouDepartment of Cell Biology, University of Alberta, Edmonton, Canada.
Natasha Malik-SoniDepartment of Molecular Genetics, University of Toronto, Toronto, Canada.
Zaikun XuDepartment of Cell Biology, University of Alberta, Edmonton, Canada.
Anil KumarDepartment of Cell Biology, University of Alberta, Edmonton, Canada.
Richard A RachubinskiDepartment of Cell Biology, University of Alberta, Edmonton, Canada.
Lori FrappierDepartment of Molecular Genetics, University of Toronto, Toronto, Canada.
Tom C HobmanDepartment of Cell Biology, University of Alberta, Edmonton, Canada Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, Canada Li Ka Shing Institute of Virology, University of Alberta, Edmonton, Canada tom.hobman@ualberta.ca.
University of Alberta · CAUniversity of Toronto · CA

Funding

Canadian Institutes of Health Research
6 · The paper itself

Abstract

unlabelledFlaviviruses are significant human pathogens that have an enormous impact on the global health burden. Currently, there are very few vaccines against or therapeutic treatments for flaviviruses, and our understanding of how these viruses cause disease is limited. Evidence suggests that the capsid proteins of flaviviruses play critical nonstructural roles during infection, and therefore, elucidating how these viral proteins affect cellular signaling pathways could lead to novel targets for antiviral therapy. We used affinity purification to identify host cell proteins that interact with the capsid proteins of West Nile and dengue viruses. One of the cellular proteins that formed a stable complex with flavivirus capsid proteins is the peroxisome biogenesis factor Pex19. Intriguingly, flavivirus infection resulted in a significant loss of peroxisomes, an effect that may be due in part to capsid expression. We posited that capsid protein-mediated sequestration and/or degradation of Pex19 results in loss of peroxisomes, a situation that could result in reduced early antiviral signaling. In support of this hypothesis, we observed that induction of the lambda interferon mRNA in response to a viral RNA mimic was reduced by more than 80%. Together, our findings indicate that inhibition of peroxisome biogenesis may be a novel mechanism by which flaviviruses evade the innate immune system during early stages of infection. IMPORTANCE: RNA viruses infect hundreds of millions of people each year, causing significant morbidity and mortality. Chief among these pathogens are the flaviviruses, which include dengue virus and West Nile virus. Despite their medical importance, there are very few prophylactic or therapeutic treatments for these viruses. Moreover, the manner in which they subvert the innate immune response in order to establish infection in mammalian cells is not well understood. Recently, peroxisomes were reported to function in early antiviral signaling, but very little is known regarding if or how pathogenic viruses affect these organelles. We report for the first time that flavivirus infection results in significant loss of peroxisomes in mammalian cells, which may indicate that targeting of peroxisomes is a key strategy used by viruses to subvert early antiviral defenses.

Indexed as

Signal TransductionDengueDengue VirusHEK293 CellsHumansMembrane ProteinsPeroxisomesWest Nile FeverWest Nile virusMembrane ProteinsPEX19 protein, human

Identifiers

PMID26423946
PMCPMC4665241
OpenAlexW2191789147

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.